What question did this study set out to answer?

Evaluate referral patterns and characteristics of patients with relapsed or refractory large B cell lymphoma receiving CAR T cell therapy in the US.

December 8, 2025BloodOpen Access

CAR T cell therapy referral patterns and characteristics of patients with relapsed or refractory (R/R) large B cell lymphoma (LBCL) in the United States

View Full Paper

Ask AI

Bookmark

Authors

Retrospective analysis shows barrier-impacting referral patterns for CAR T therapy in large B cell lymphoma patients.

Evaluate referral patterns and characteristics of patients with relapsed or refractory large B cell lymphoma receiving CAR T cell therapy in the US.
Used retrospective cohort study design utilizing US claims data from Komodo Health® database.
Identified eligible patients with multiple diagnoses of large B cell lymphoma and continuous claims enrollment.
Assessed referral rates among patients treated at non-CAR T sites and compared baseline characteristics based on referral status.
Analyzed treatment rates for patients referred to CAR T sites across different lines of therapy.
Of 8959 eligible patients, 3068 (34%) remained at a CAR T site throughout treatment.
15% of patients received CAR T therapy, with referral rates varying based on line of therapy.
Differences in demographic characteristics based on referral status were notable, including age and insurance type.

Shadman et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark